Dr. Sergio Jaramillo, MD
Sleep Medicine (Sleep Medicine (Psychiatry & Neurology) Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 346
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Sleep Medicine (Psychiatry & Neurology) Physician primary
FL license ME102465 -
Neurology Physician
FL license ME102465
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Hospital of Miami Miami, FL
- South Miami Hospital Miami, FL
- West Kendall Baptist Hospital Miami, FL
- Homestead Hospital Homestead, FL
- Fishermen's Community Hospital Marathon, FL
Medical groups
- Neuroscience Consultants LLP (115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 346
- Services billed
- 1,116
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 414 | 204 |
| Established patient office or other outpatient visit, 30-39 minutes | 93 | 71 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 80 | 40 |
| Annual depression screening, 5 to 15 minutes | 58 | 58 |
| New patient office or other outpatient visit, 60-74 minutes | 51 | 51 |
| Measurement of brain wave activity (eeg), awake and drowsy | 41 | 41 |
| Nerve conduction, 5-6 studies | 32 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 30 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 28 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 27 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Miami, FL | 267 |
| Donepezil Hcl Other prescribers in Miami, FL | 138 |
| Gabapentin Other prescribers in Miami, FL | 127 |
| Rasagiline Mesylate | 119 |
| Escitalopram Oxalate Other prescribers in Miami, FL | 92 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Miami, FL | 91 |
| Memantine Hcl Er (memantine hcl) Other prescribers in Miami, FL | 88 |
| Quetiapine Fumarate Other prescribers in Miami, FL | 71 |
| Gocovri (amantadine hcl) Other prescribers in Miami, FL | 71 |
| Trazodone Hcl Other prescribers in Miami, FL | 70 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 37 companies reported 172 payments worth $5,653 in total to this clinician.
| Pfizer Inc. | $1,306 |
|---|---|
| AbbVie Inc. | $609 |
| UCB, Inc. | $468 |
| Jazz Pharmaceuticals Inc. | $422 |
| Inspire Medical Systems, Inc. | $304 |
| Novartis Pharmaceuticals Corporation | $181 |
| Lilly USA, LLC | $167 |
| Janssen Biotech, Inc. | $157 |
| Food and Beverage | $3,989 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,263 |
| Education | $400 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) ZAVZPRET · PAIN | $1,220 |
| Teva Pharmaceuticals USA, Inc. May 9, 2025 | Education in-kind | $111 |
| Jazz Pharmaceuticals Inc. Feb 26, 2025 | Education XYWAV · NEUROLOGY · in-kind | $99.99 |
| Janssen Biotech, Inc. Nov 20, 2025 | Education in-kind | $99.00 |
| Jazz Pharmaceuticals Inc. Jul 7, 2025 | Education XYWAV · NEUROLOGY · in-kind | $89.99 |
| Mdd US Operations, LLC Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Apokyn · APOMORPHINE HYDROCHLORIDE | $15.64 |
| Mdd US Operations, LLC Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) Apokyn · APOMORPHINE HYDROCHLORIDE | $15.55 |
| Mdd US Operations, LLC Jul 9, 2025 | Compensation for services other than consulting (speaking, faculty) Apokyn · APOMORPHINE HYDROCHLORIDE | $11.92 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $29,711 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787 - An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV
Jazz Pharmaceuticals Inc. - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Alkermes, Inc. · Active, not recruiting · NCT06843590
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.